The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
The Pharmacological Basis of Therapeutics
Goodman, L., & Gilhan, A. (1941) · Anesthesiology · doi:10.1097/00000542-194105000-00013 · Cited by 2,146
WHO technical report series 200 (1960).
Pittman, M. (1974) · PubMed · Cited by 1,448
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
The Pharmacological Basis of Therapeutics
Faddis, M. O., Goodman, L., & Gilman, A. (1941) · The American Journal of Nursing · doi:10.2307/3414719 · Cited by 929
Pharmacogenetics. Heredity and the Response to Drugs.
(1963) · Annals of Internal Medicine · doi:10.7326/0003-4819-58-4-757 · Cited by 242
ACETOPHENETIDIN‐INDUCED METHEMOGLOBINEMIA*
Shahidi, N. T. (1968) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1968.tb48266.x · Cited by 73
Influence of the defective metabolism of sparteine on its pharmacokinetics
Eichelbaum, M. F., Spannbrucker, N., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562060 · Cited by 66
Self-citationPropping, P. (1978) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/3-540-08907-1_4 · Cited by 26
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Self-citationPolymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM
Meyer, U. A., & Zanger, U. M. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.269 · Cited by 549
Bertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Streetman, D. S., Bertino, J. S., & Nafziger, A. N. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00001 · Cited by 425
Pharmacogenetics – five decades of therapeutic lessons from genetic diversity
Meyer, U. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1428 · Cited by 420
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Self-citationPharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Alv�n, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316090 · Cited by 361
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Enzymatic activation of chemicals to toxic metabolites
Guengerich, F. P., Liebler, D. C., & Reed, D. L. (1985) · CRC Critical Reviews in Toxicology · doi:10.3109/10408448509037460 · Cited by 334
Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species
Guengerich, F. P. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00068-9 · Cited by 330
Pharmacogenomics: bench to bedside
Weinshilboum, R., & Wang, L. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1497 · Cited by 320
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Pharmacogenetics of drug metabolism
Kalow, W. (1980) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(80)90063-2 · Cited by 289
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
Role of Cytochrome P450 Enzymes in Drug-Drug Interactions
Guengerich, F. P. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60200-8 · Cited by 284
Gender-related differences in pharmacokinetics and their clinical significance
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00246.x · Cited by 281
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Addressing phenoconversion: the Achilles' heel of personalized medicine
Shah, R. R., & Smith, R. L. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278
Pharmacogenomics: The promise of personalized medicine
Mancinelli, L., Cronin, M., & Sadée, W. (2000) · AAPS PharmSci · doi:10.1208/ps020104 · Cited by 267
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6
Zanger, U. M., Fischer, J., Raimundo, S., Stüven, T., Evert, B. O., Schwab, M., & Eichelbaum, M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00004 · Cited by 266
Self-citationL??tsch, J., Skarke, C., Liefhold, J., & Geisslinger, G. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443140-00003 · Cited by 256
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241
Cardiovascular pharmacogenomics and individualized drug therapy
Pereira, N. L., & Weinshilboum, R. M. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.154 · Cited by 72
Metadata
- Authors
- Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1979
- Volume
- 16
- Issue
- 3
- Pages
- 183-187
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2003410018
- Cited by
- 632
- References
- 9
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.